AEZS - Aeterna Zentaris Inc.
| Previous Close | 1.65 |
| Open | 1.65 |
| Bid | 1.55 x 6300 |
| Ask | 1.68 x 100 |
| Day's Range | 1.60 - 1.65 |
| 52 Week Range | 0.78 - 3.75 |
| Volume | 84,679 |
| Avg. Volume | 140,501 |
| Market Cap | 25.864M |
| Beta | 1.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.12 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.50 |
Yahoo Finance Video•4 months agoAeterna Zentaris jumps on FDA approval, Honda bets on solid-state battery, Rolling Stone is sold
Aeterna Zentaris, Honda, Rolling Stone and Didi Chuxing are the companies to watch.
Yahoo Finance Video•4 months agoYahoo Finance Live: Market Movers - Dec 21st, 2017
Yahoo Finance's LIVE stock market coverage and analysis.
- ACCESSWIRE•8 days ago
Wired News – Anavex Life Sciences To Commence Phase-2 Study of ANAVEX(R)2-73 in Parkinson’s Disease Dementia
Stock Monitor: Aeterna Zentaris Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on Anavex Life Sciences Corp. (NASDAQ: AVXL ...
- GlobeNewswire•17 days ago
Aeterna Zentaris Files Management Information Circular
CHARLESTON, S.C., April 09, 2018-- Aeterna Zentaris Inc. is pleased to announce that it has filed its Management Information Circular for the upcoming Annual and Special Meeting of Shareholders. The Meeting ...
- Associated Press•29 days ago
Aeterna Zentaris reports 4Q loss
On a per-share basis, the Montreal-based company said it had a loss of 3 cents. Losses, adjusted for pretax gains, came to 24 cents per share. The drug developer posted revenue of $178,000 in the period. ...
- GlobeNewswire•last month
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2017 Financial and Operating Results
CHARLESTON, S.C., March 28, 2018-- Aeterna Zentaris Inc. today reported financial and operating results for the fourth quarter and year ended December 31, 2017.. All Amounts are in U.S. Food and Drug Administration ...
- ACCESSWIRE•last month
Aeterna Zentaris Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 28, 2018 / Aeterna Zentaris Inc. (NASDAQ: AEZS ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 28, 2018, at 8:30 AM Eastern Time. ...
- Simply Wall St.•last month
March Best Growth Stocks
Companies such as Emblem and Aeterna Zentaris have a significantly positive future outlook on the basis of their profitability and returns. Investors seeking to enhance their portfolio should consider theseRead More...
- GlobeNewswire•last month
Aeterna Zentaris to Announce Fourth Quarter and Year End 2017 Financial and Operating Results on March 28th, 2018
CHARLESTON, S.C., March 21, 2018-- Aeterna Zentaris Inc. will announce its fourth quarter and year ended December 31, 2017 financial and operating results after market close on Tuesday, March 27 th, 2018. ...
- GlobeNewswire•2 months ago
Aeterna Zentaris Appoints James Clavijo as Chief Financial Officer
CHARLESTON, S.C., March 05, 2018-- Aeterna Zentaris Inc. today announced the appointment of James Clavijo as Chief Financial Officer effective March 5, 2018. Clavijo joins Aeterna Zentaris from Tri-Source ...
- GlobeNewswire•2 months ago
Aeterna Zentaris Provides Update on Previously Disclosed Class Action Lawsuit
CHARLESTON, S.C., March 05, 2018-- Aeterna Zentaris Inc. and announced today that the United States District Court for the District of New Jersey has granted a motion for class certification in the previously ...
- Simply Wall St.•2 months ago
Top TSX Growth Stocks To Buy
Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as Knight Therapeutics and Callidus Capital are deemed to be superiorRead More...
- InvestorPlace•3 months ago
5 Great Breakout Stocks Offering Superlative Returns
In order to select the right breakout stock one has to first calculate its support and resistance level. A support level is the lower bound for stock movements while a resistance level refers to the maximum price which it trades within over a considerable period. In other words, the demand for a stock is at its lowest at its support level, which means most traders are willing to sell it.
- Zacks•3 months ago
Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service
Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service
- Zacks•3 months ago
5 Great Breakout Stocks Offering Superlative Returns
This method involved zeroing in on those stocks whose prices are varying within a narrow band.
- Market Exclusive•3 months ago
Here’s What’s Moving Novartis And Aeterna Zentaris Right Now
Novartis (NYSE: NVS) and Aeterna Zentaris Inc. (NASDAQ: AEZS) both saw spikes in volume and subsequent share price movement in the biotechnology and healthcare markets during the middle of this week. Here’s what happened with each and what comes next. Novartis This biotechnology behemoth reported on Wednesday that the US Food and Drug Administration (FDA) […] The post Here’s What’s Moving Novartis And Aeterna Zentaris Right Now appeared first on Market Exclusive.
- SmarterAnalyst•3 months ago
AEterna Zentaris Inc. (USA) (AEZS) Stock Fires Up to the Roof; Here’s Why
AEterna Zentaris Inc. (USA)(NASDAQ:AEZS) investors are busy throwing a party today following the news that tiny drug maker has sold its U.S. and Canadian rights to MACRILEN™ (macimorelin), a drug designed to evaluate adults for growth hormone deficiency, to Strongbridge Biopharma (NASDAQ:SBBP). Under the terms of the license and assignment agreement, Strongbridge will make an upfront payment of $24 million to Aeterna Zentaris within five days of the effective date of the agreement. Strongbridge has agreed to pay tiered royalties in the mid-to-high teens as a percentage of net sales as well as milestone payments upon FDA approval of a pediatric indication and the achievement of pre-determined sales levels. The license and assignment agreement also provides Strongbridge with an exclusive license to manufacture and commercialize MACRILEN in the U.S. and Canada.
- Yahoo Finance•4 months ago
Aeterna Zentaris jumps on FDA approval, Honda bets on solid-state battery, Rolling Stone is sold
Aeterna Zentaris, Honda, Rolling Stone and Didi Chuxing are the companies to watch.
- Yahoo Finance•4 months ago
Stocks push slightly higher, President Trump prepares to sign tax bill into law
Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:25 a.m. ET.
- Newsfile•4 months ago
IIROC Trade Resumption - Aeterna Zentaris Inc.
Toronto, Ontario--(Newsfile Corp. - December 21, 2017) - Trading resumes in: Company: Aeterna Zentaris Inc. TSX Symbol: AEZS (all issues) ...
- Market Exclusive•4 months ago
Here’s How AbbVie (NYSE:ABBV) and Aeterna Zentaris Inc. (NASDAQ:AEZS) Just Picked Up Early Christmas Present
We are quickly closing in on the end of the week and it’s been a pretty big one in the biotechnology space for a whole host of reasons. The FDA scored a record number of approvals for the year with a trio of unexpected, early green lights and some of the biggest names in the […] The post Here’s How AbbVie (NYSE:ABBV) and Aeterna Zentaris Inc. (NASDAQ:AEZS) Just Picked Up Early Christmas Present appeared first on Market Exclusive.
